(Q27851797)

13 November 2016

title

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma (English)

1 reference

PubMed

PubMed publication ID

22596232

13 November 2016

main subject

hepatocellular carcinoma

1 reference

M Kudo

2

0 references

author name string

S Hagiwara

1

0 references

T Nagai

3

0 references

T Inoue

4

0 references

K Ueshima

5

0 references

N Nishida

6

0 references

T Watanabe

7

0 references

T Sakurai

British Journal of Cancer

8

0 references

language of work or name

English

0 references

publication date

5 June 2012

0 references

published in

0 references

volume

106

0 references

issue

12

0 references

page(s)

1997-2003

0 references

cites work

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Mammalian MAP kinase signalling cascades

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

MAP kinase signalling pathways in cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Tumour stem cells and drug resistance

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Signaling pathways governing tumor angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Identification and characterization of tumorigenic liver cancer stem/progenitor cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388555

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

29 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.145

Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.145

c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.145

p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.145

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22596232

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22596232

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.145

1 reference

Dimensions Publication ID

1050722885

0 references

1 reference

1 reference

PubMed publication ID

22596232

1 reference